Coronary heart disease policy models: a systematic review
- Experts debate using risk or expected benefit for determining when to start stain therapy. // Formulary;Nov99, Vol. 34 Issue 11, p908
Presents perspectives on the use of statin therapy for primary prevention of coronary artery diseases. Initiation of statins for primary prevention guided by the risk of future cardiovascular events; Multifactorial approach to guide treatment decisions; Statin therapy guided by the expected...
- Pets that heal. // Consumer Reports on Health;Oct93, Vol. 5 Issue 10, p109
Suggests the role of pets in fighting coronary heart disease. Research from Purdue University showing lower blood pressure and cholesterol levels of pet owners; Quality of relationships with other people of pet owners; Alleviation of psychological and social factors.
- Ticagrelor's efficacy outweighs generic clopidogrel's low price. // PharmacoEconomics & Outcomes News;7/16/2011, Issue 633, p3
The article focuses on a study of the cost effectiveness of using ticagrelor in the secondary prevention of acute coronary syndromes (ACS) compared with clopidogrel treatment conducted by D. J. Crespin and colleagues and published in the June 2011 issue of "Value in Health."
- Exercise, drug interventions may produce similar outcomes on mortality. // Endocrine Today;Nov2013, Vol. 11 Issue 11, p16
The article discusses a study published in a 2013 issue of the "British Medical Journal" which found that exercise and drug interventions appear to have similar mortality benefits in the prevention of coronary heart disease and diabetes, rehabilitation after stroke and treatment of heart failure.
- Should all postmenopausal women receive estrogen? No easy answers. // Modern Medicine;Apr94, Vol. 62 Issue 4, p32
Discusses whether physicians should routinely prescribe estrogen for post-menopausal women to ward off coronary heart disease (CHD). Absence of randomized prospective trial to recommend estrogen for CHD; Lower risk of CHD among estrogen users.
- Cardiovascular protection extends to women who use progestin with estrogen. // Modern Medicine;Dec96, Vol. 64 Issue 12, p22
Discusses a study conducted by physician Francine Grodstein and colleagues which revealed that estrogen therapies that include progestin provide a degree of protection against heart disease that is similar to that of estrogen alone. Effectiveness of progestin and estrogen in lowering incidence...
- Epidemiology and costs of diabetes mellitus in Switzerland: an analysis of health care claims data, 2006 and 2011. Huber, Carola A.; Schwenkglenks, Matthias; Rapold, Roland; Reich, Oliver // BMC Endocrine Disorders;2014, Vol. 14 Issue 1, p19
Background Quantifying the burden of diabetes mellitus is fundamental for managing patients in health service delivery systems and improves the understanding of the importance of prevention and early intervention of diabetes. In Switzerland, epidemiological data on diabetes are very scarce. In...
- Knowledge and Practice Assessment of Workers in a Pharmaceutical Company about Prevention of Coronary Artery Disease. Attarchi, Mirsaeed; Mohammadi, Saber; Nojomi, Marzieh; Labbafinejad, Yasser // Acta Medica Iranica;2012, Vol. 50 Issue 10, p697
Coronary artery disease is one of the most common reasons of death around the world. Also, according to previous studies, the incidence of coronary artery disease is rapidly increasing in developing countries such as Iran. The aim of this study was to evaluate the knowledge and practice of...
- Full Medicare prescription coverage beneficial post-MI. // PharmacoEconomics & Outcomes News;4/19/2008, Issue 551, p3
The article discusses research being done on the benefits of full Medicare drug coverage to post-myocardial infarction (MI) Medicare beneficiaries. It references a study by N. K. Choudry et al, published in the March 11, 2008 issue of "Circulation." It notes that full prescription coverage for...